O	0	10	Randomized
O	11	22	multicenter
O	23	28	trial
O	29	31	of
B-intervention	32	40	sentinel
I-intervention	41	45	node
I-intervention	46	52	biopsy
O	53	59	versus
B-control	60	68	standard
I-control	69	77	axillary
I-control	78	87	treatment
O	88	90	in
O	91	99	operable
O	100	106	breast
O	107	113	cancer
O	113	114	:
O	115	118	the
O	119	126	ALMANAC
O	127	132	Trial
O	132	133	.

O	134	142	Sentinel
O	143	148	lymph
O	149	153	node
O	154	160	biopsy
O	161	163	in
O	164	169	women
O	170	174	with
O	175	183	operable
O	184	190	breast
O	191	197	cancer
O	198	200	is
O	201	210	routinely
O	211	215	used
O	216	218	in
O	219	223	some
O	224	233	countries
O	234	237	for
O	238	245	staging
O	246	249	the
O	250	256	axilla
O	257	264	despite
O	265	272	limited
O	273	277	data
O	278	282	from
O	283	293	randomized
O	294	300	trials
O	301	303	on
O	304	313	morbidity
O	314	317	and
O	318	327	mortality
O	328	336	outcomes
O	336	337	.

O	338	340	We
O	341	350	conducted
O	351	352	a
O	353	364	multicenter
O	365	375	randomized
O	376	381	trial
O	382	384	to
O	385	392	compare
O	393	400	quality
O	400	401	-
O	401	403	of
O	403	404	-
O	404	408	life
O	409	417	outcomes
O	418	425	between
B-eligibility	426	434	patients
I-eligibility	435	439	with
I-eligibility	440	450	clinically
I-eligibility	451	455	node
I-eligibility	455	456	-
I-eligibility	456	464	negative
I-eligibility	465	473	invasive
I-eligibility	474	480	breast
I-eligibility	481	487	cancer
O	488	491	who
O	492	500	received
O	501	509	sentinel
O	510	515	lymph
O	516	520	node
O	521	527	biopsy
O	528	531	and
O	532	540	patients
O	541	544	who
O	545	553	received
O	554	562	standard
O	563	571	axillary
O	572	581	treatment
O	581	582	.

O	583	586	The
O	587	594	primary
O	595	602	outcome
O	603	611	measures
O	612	616	were
B-outcome-Measure	617	620	arm
I-outcome-Measure	621	624	and
I-outcome-Measure	625	633	shoulder
I-outcome-Measure	634	643	morbidity
O	644	647	and
B-outcome-Measure	648	655	quality
I-outcome-Measure	656	658	of
I-outcome-Measure	659	663	life
O	663	664	.

O	665	669	From
O	670	678	November
O	679	683	1999
O	684	686	to
O	687	694	October
O	695	699	2003
O	699	700	,
B-total-participants	701	705	1031
O	706	714	patients
O	715	719	were
O	720	728	randomly
O	729	737	assigned
O	738	740	to
O	741	748	undergo
O	749	757	sentinel
O	758	763	lymph
O	764	768	node
O	769	775	biopsy
O	776	777	(
O	777	778	n
O	779	780	=
B-intervention-participants	781	784	515
O	784	785	)
O	786	788	or
O	789	797	standard
O	798	806	axillary
O	807	814	surgery
O	815	816	(
O	816	817	n
O	818	819	=
B-control-participants	820	823	516
O	823	824	)
O	824	825	.

O	826	834	Patients
O	835	839	with
O	840	848	sentinel
O	849	854	lymph
O	855	859	node
O	860	870	metastases
O	871	880	proceeded
O	881	883	to
O	884	891	delayed
O	892	900	axillary
O	901	910	clearance
O	911	913	or
O	914	922	received
O	923	931	axillary
O	932	944	radiotherapy
O	945	946	(
O	946	955	depending
O	956	958	on
O	959	962	the
O	963	971	protocol
O	972	974	at
O	975	978	the
O	979	987	treating
O	988	999	institution
O	999	1000	)
O	1000	1001	.

O	1002	1011	Intention
O	1011	1012	-
O	1012	1014	to
O	1014	1015	-
O	1015	1020	treat
O	1021	1029	analyses
O	1030	1032	of
O	1033	1037	data
O	1038	1040	at
O	1041	1042	1
O	1042	1043	,
O	1044	1045	3
O	1045	1046	,
O	1047	1048	6
O	1048	1049	,
O	1050	1053	and
O	1054	1056	12
O	1057	1063	months
O	1064	1069	after
O	1070	1077	surgery
O	1078	1081	are
O	1082	1091	presented
O	1091	1092	.

O	1093	1096	All
O	1097	1108	statistical
O	1109	1114	tests
O	1115	1119	were
O	1120	1123	two
O	1123	1124	-
O	1124	1129	sided
O	1129	1130	.

O	1131	1134	The
O	1135	1143	relative
O	1144	1149	risks
O	1150	1152	of
B-outcome	1153	1156	any
I-outcome	1157	1167	lymphedema
O	1168	1171	and
B-outcome	1172	1179	sensory
I-outcome	1180	1184	loss
O	1185	1188	for
O	1189	1192	the
O	1193	1201	sentinel
O	1202	1207	lymph
O	1208	1212	node
O	1213	1219	biopsy
O	1220	1225	group
O	1226	1234	compared
O	1235	1239	with
O	1240	1243	the
O	1244	1252	standard
O	1253	1261	axillary
O	1262	1271	treatment
O	1272	1277	group
B-outcome	1278	1280	at
I-outcome	1281	1283	12
I-outcome	1284	1290	months
O	1291	1295	were
O	1296	1297	0
O	1297	1298	.
O	1298	1300	37
O	1301	1302	(
O	1302	1304	95
O	1304	1305	%
O	1306	1316	confidence
O	1317	1325	interval
O	1326	1327	[
O	1327	1329	CI
O	1329	1330	]
O	1331	1332	=
O	1333	1334	0
O	1334	1335	.
O	1335	1337	23
O	1338	1340	to
O	1341	1342	0
O	1342	1343	.
O	1343	1345	60
O	1345	1346	;
O	1347	1355	absolute
O	1356	1361	rates
O	1361	1362	:
B-iv-bin-percent	1363	1364	5
I-iv-bin-percent	1364	1365	%
O	1366	1372	versus
B-cv-bin-percent	1373	1375	13
I-cv-bin-percent	1375	1376	%
O	1376	1377	)
O	1378	1381	and
O	1382	1383	0
O	1383	1384	.
O	1384	1386	37
O	1387	1388	(
O	1388	1390	95
O	1390	1391	%
O	1392	1394	CI
O	1395	1396	=
O	1397	1398	0
O	1398	1399	.
O	1399	1401	27
O	1402	1404	to
O	1405	1406	0
O	1406	1407	.
O	1407	1409	50
O	1409	1410	;
O	1411	1419	absolute
O	1420	1425	rates
O	1425	1426	:
B-iv-bin-percent	1427	1429	11
I-iv-bin-percent	1429	1430	%
O	1431	1437	versus
B-cv-bin-percent	1438	1440	31
I-cv-bin-percent	1440	1441	%
O	1441	1442	)
O	1442	1443	,
O	1444	1456	respectively
O	1456	1457	.

B-outcome	1458	1463	Drain
I-outcome	1464	1469	usage
O	1469	1470	,
B-outcome	1471	1477	length
I-outcome	1478	1480	of
I-outcome	1481	1489	hospital
I-outcome	1490	1494	stay
O	1494	1495	,
O	1496	1499	and
B-outcome	1500	1504	time
I-outcome	1505	1507	to
I-outcome	1508	1518	resumption
I-outcome	1519	1521	of
I-outcome	1522	1528	normal
I-outcome	1529	1532	day
I-outcome	1532	1533	-
I-outcome	1533	1535	to
I-outcome	1535	1536	-
I-outcome	1536	1539	day
I-outcome	1540	1550	activities
O	1551	1556	after
O	1557	1564	surgery
O	1565	1569	were
O	1570	1583	statistically
O	1584	1597	significantly
O	1598	1603	lower
O	1604	1606	in
O	1607	1610	the
O	1611	1619	sentinel
O	1620	1625	lymph
O	1626	1630	node
O	1631	1637	biopsy
O	1638	1643	group
O	1644	1645	(
O	1645	1648	all
O	1649	1650	P
O	1651	1652	<
O	1653	1654	.
O	1654	1657	001
O	1657	1658	)
O	1658	1659	,
O	1660	1663	and
O	1664	1672	axillary
O	1673	1682	operative
O	1683	1687	time
O	1688	1691	was
O	1692	1699	reduced
O	1700	1701	(
O	1701	1702	P
O	1703	1704	=
O	1705	1706	.
O	1706	1709	055
O	1709	1710	)
O	1710	1711	.

O	1712	1719	Overall
O	1720	1727	patient
O	1727	1728	-
O	1728	1736	recorded
B-outcome	1737	1744	quality
I-outcome	1745	1747	of
I-outcome	1748	1752	life
I-outcome	1753	1756	and
I-outcome	1757	1760	arm
I-outcome	1761	1772	functioning
I-outcome	1773	1779	scores
O	1780	1784	were
O	1785	1798	statistically
O	1799	1812	significantly
O	1813	1819	better
O	1820	1822	in
O	1823	1826	the
O	1827	1835	sentinel
O	1836	1841	lymph
O	1842	1846	node
O	1847	1853	biopsy
O	1854	1859	group
O	1860	1870	throughout
O	1871	1872	(
O	1872	1875	all
O	1876	1877	P
O	1878	1879	<
O	1880	1882	or
O	1883	1884	=
O	1885	1886	.
O	1886	1889	003
O	1889	1890	)
O	1890	1891	.

O	1892	1897	These
O	1898	1906	benefits
O	1907	1911	were
O	1912	1916	seen
O	1917	1921	with
O	1922	1924	no
O	1925	1933	increase
O	1934	1936	in
B-outcome	1937	1944	anxiety
I-outcome	1945	1951	levels
O	1952	1954	in
O	1955	1958	the
O	1959	1967	sentinel
O	1968	1973	lymph
O	1974	1978	node
O	1979	1985	biopsy
O	1986	1991	group
O	1992	1993	(
O	1993	1994	P
O	1995	1996	>
O	1997	1998	.
O	1998	2000	05
O	2000	2001	)
O	2001	2002	.

O	2003	2011	Sentinel
O	2012	2017	lymph
O	2018	2022	node
O	2023	2029	biopsy
O	2030	2032	is
O	2033	2043	associated
O	2044	2048	with
O	2049	2056	reduced
O	2057	2060	arm
O	2061	2070	morbidity
O	2071	2074	and
O	2075	2081	better
O	2082	2089	quality
O	2090	2092	of
O	2093	2097	life
O	2098	2102	than
O	2103	2111	standard
O	2112	2120	axillary
O	2121	2130	treatment
O	2131	2134	and
O	2135	2141	should
O	2142	2144	be
O	2145	2148	the
O	2149	2158	treatment
O	2159	2161	of
O	2162	2168	choice
O	2169	2172	for
O	2173	2181	patients
O	2182	2185	who
O	2186	2190	have
O	2191	2196	early
O	2196	2197	-
O	2197	2202	stage
O	2203	2209	breast
O	2210	2216	cancer
O	2217	2221	with
O	2222	2232	clinically
O	2233	2241	negative
O	2242	2247	nodes
O	2247	2248	.
